Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Won Suk LeeDong Sung KimJeong Hun KimYoonki HeoHannah YangEun-Jin GoJin Hyoung KimSeung Joon LeeByung Cheol AhnJung Sun YumHong Jae ChonJoo Hoon KimPublished in: Journal for immunotherapy of cancer (2022)
Our study demonstrated that intratumoral LP treatment improves the innate and adaptive antitumor immunity within the TME and enhances the efficacy of αPD-1 and αCTLA-4 immune checkpoint blockade.